title: Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
abstract: BACKGROUND
  No standard chemotherapy regimen has been established for unresectable or recurrent small bowel adenocarcinoma (SBA).
  
  
  METHODS
  Clinical courses of 132 patients with unresectable or recurrent SBA who received chemotherapy at 41 institutions in Japan were reviewed retrospectively. Patients were classified into five groups according to first-line chemotherapy regimens: fluoropyrimidine monotherapy (group A), fluoropyrimidine-cisplatin (group B), fluoropyrimidine-oxaliplatin (group C), fluoropyrimidine-irinotecan (group D), and other regimens (group E).
  
  
  RESULTS
  The number of patients in each group was as follows: groups A, 60 patients; group B, 17 patients; group C, 22 patients; group D, 11 patients; and group E, 22 patients. Median progression-free survival (PFS) times were as follows: group A, 5.4 months; group B, 3.8 months; group C, 8.2 months; group D, 5.6 months; and group E, 3.4 months. Median overall survival (OS) times were as follows: group A, 13.9 months; group B, 12.6 months; group C, 22.2 months; group D, 9.4 months; and group D, 8.1 months. Patients in group C achieved significantly longer PFS times and substantially (but not significantly) longer OS times than patients in group A. After adjusting for clinical background characteristics, fluoropyrimidine-oxaliplatin therapy was a significant positive prognostic factor for PFS and OS times.
  
  
  CONCLUSIONS
  The results suggest that fluoropyrimidine-oxaliplatin combination therapy is the most promising first-line chemotherapy regimen for unresectable or recurrent SBA.
authors.affiliation: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, Japan. t.tsushima@scchr.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tsushima
authors.forename: Masataka
authors.initials: M
authors.lastname: Taguri
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Honma
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Shinya
authors.initials: S
authors.lastname: Ueda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Nishina
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kawai
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Suenaga
authors.forename: Fumio
authors.initials: F
authors.lastname: Tamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Morita
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology*; D000077146:Irinotecan; D007564:Japan; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D009944:Organoplatinum Compounds; D011743:Pyrimidines; D000077150:Oxaliplatin; C029269:5-fluoropyrimidine; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin